SK Biopharmaceuticals
SK Biopharmaceuticals Co Ltd is a South Korean biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for central nervous system disorders and oncology. The company's lead commercial therapy, cenobamate, is an anti-seizure medication marketed globally under the brand Cenobamate and Xcopri for focal-onset seizures in adults. Its drug research pipeline focuses on novel small molecule candidates targeting epilepsy, brain tumors, and psychiatric disorders. Principal revenue is derived from direct commercial pharmaceutical sales in the United States, international licensing milestone royalties, and active pharmaceutical ingredient supply agreements with global partners. SK Biopharmaceuticals is a leading South Korean biopharmaceutical innovator, operating as a consolidated subsidiary of the SK Group conglomerate. Headquartered in Seongnam, South Korea, the company's common shares are publicly listed and traded on the Korea Exchange under the ticker 326030.
8 of the funds FundTelligence covers report a position in SK Biopharmaceuticals.
- Legal name
- SK Biopharmaceuticals Co. Ltd.
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 8
Funds holding SK Biopharmaceuticals
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.22 % (full portfolio disclosed, October 2026)
- KLP AksjeFremvoksende Markeder Flerfaktor — KLP · 0.16 % (full portfolio disclosed, June 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.03 % (full portfolio disclosed, December 2025)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- Storebrand Emerging Markets — Storebrand · 0.01 % (full portfolio disclosed, October 2026)
- Storebrand Indeks Alle Markeder — Storebrand · 0.0 % (full portfolio disclosed, October 2026)